Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Australian Descriptive Epidemiology Study of Severity of Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS) and Exposure to Biological Disease Modifying Anti-rheumatic Drugs (bDMARDs)

NCT00751387 is registered in ClinicalTrials.gov with Wyeth is now a wholly owned subsidiary of Pfizer as lead sponsor.

NCT NCT00751387
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00751387 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Australian Descriptive Epidemiology Study of Severity of Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS) and Exposure to Biological Disease Modifying Anti-rheumatic Drugs (bDMARDs)
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Phase
Observational
Overall status
Completed
Start date
November 30, 2008
Completion date
September 30, 2009
Enrollment
559 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis